coBRIM: A phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

Paolo A. Ascierto, Grant A. McArthur, Brigitte Dréno, James Larkin, Gabriella Liszkay, Michele Maio, Mario Mandala, Lev Demidov, Daniil Stroyakovskiy, Luc Thomas, Luis de la Cruz-Merino, Victoria Atkinson, Caroline Dutriaux, Claus Garbe, Ilsung Chang, Stephen P. Hack, Antoni Ribas

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1-2
Number of pages2
JournalJournal of Translational Medicine
DOIs
Publication statusAccepted/In press - Jan 15 2015

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Ascierto, P. A., McArthur, G. A., Dréno, B., Larkin, J., Liszkay, G., Maio, M., Mandala, M., Demidov, L., Stroyakovskiy, D., Thomas, L., de la Cruz-Merino, L., Atkinson, V., Dutriaux, C., Garbe, C., Chang, I., Hack, S. P., & Ribas, A. (Accepted/In press). coBRIM: A phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAF V600 mutation-positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). Journal of Translational Medicine, 1-2. https://doi.org/10.1186/1479-5876-13-S1-O4